Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Blood (2023) 142 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2023-185751

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study from the Société Francophone De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

Blood (2023) 142 (Supplement 1): 2235.

https://doi.org/10.1182/blood-2023-184383

Published: 2023

Journal Articles

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Blood (2023) 142 (Supplement 1): 445.

https://doi.org/10.1182/blood-2023-181571

Published: 2023

Journal Articles

Checkpoint Inhibitors and Allo-SCT in Hodgkin Lymphoma: A Matter of Time - a Study By the SFGM-TC

Blood (2023) 142 (Supplement 1): 4926.

https://doi.org/10.1182/blood-2023-184836

Published: 2023

Journal Articles

The Occurrence of Infection and TP53 Mutation Are Risk Factors for Cardiovascular Toxicity of Acute Myeloid Leukemia Induction Therapy

Hélène Kemp, Laurène Fenwarth, Delphine Lebon, Nicolas Duployez, Etienne Paubelle, Magalie Joris, Amandine Charbonnier, Lydia Montes, Claude Preudhomme, Christophe Tribouilloy, Jean Pierre Marolleau, Pierre Morel

Blood (2023) 142 (Supplement 1): 3815.

https://doi.org/10.1182/blood-2023-190177

Published: 2023

Journal Articles

Comparison of Two Reduced Intensity Conditioning Regimens (Baltimore with Clofarabine vs Thiotepa-Busulfan-Fludarabine) in Adults Receiving Peripheral Blood Stem Cell Haploidentical Transplantation for Myeloid Malignancies: A Retrospective Study of the SFGM-TC

Blood (2023) 142 (Supplement 1): 3530.

https://doi.org/10.1182/blood-2023-180581

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in the Elderly Results in Similar Survival with Matched Related or Unrelated and Haploidentical Donors: A Report from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Blood (2023) 142 (Supplement 1): 3604.

https://doi.org/10.1182/blood-2023-184995

Published: 2023

Journal Articles

Interleukin 10 (IL10) and IL15 Significantly Decreased in Chronic Myeloid Leukemia Patients Presenting with Tyrosine Kinase Inhibitor (TKI) Withdrawal Syndrome (TWS). Results from the Prospective, Explorative and Multicenter « Kiwis » Study Designed for TWS. Clinicaltrial.Gov ID: NCT03996096; Study Number: 18-206

Hyacinthe A. Johnson-Ansah, Anaïs Briant, Amandine Charbonnier, Nathalie Cambier, Gandhi Laurent Damaj, Pascal Lenain, Alexandra Henry, Jean-Jacques Parienti, David Guenet, Anne-Claire GAC Besnard, Baptiste Delapierre, Franck E. Nicolini, Brigitte Le Mauff, Marc G. Berger

Blood (2023) 142 (Supplement 1): 6335.

https://doi.org/10.1182/blood-2023-177651

Published: 2023

Journal Articles

Dose of IV Busulfan in Reduced Toxicity Conditioning Regimen for Older and/or Frail Patients with AML or MDS

Raynier Devillier, Edouard Forcade, Jacques-Olivier Bay, Anne Huynh, Anna Berceanu, Régis Peffault de Latour, Claude-Eric Bulabois, Mohamad Mohty, Michael Loschi, Emmanuelle Tavernier, Micha Srour, Patrice Chevallier, Amandine Charbonnier, Aline Schmidt, Didier Blaise

Blood (2022) 140 (Supplement 1): 2381–2382.

https://doi.org/10.1182/blood-2022-164511

Published: 2022

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France

Blood (2022) 140 (Supplement 1): 276–278.

https://doi.org/10.1182/blood-2022-163340

Published: 2022

Journal Articles

Standard Risk-Assessment of AML Doesn't Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy

Laura Simon, Alexis Caulier, Celine Berthon, Thomas Boyer, Véronique Harrivel, Magalie Joris, Amandine Charbonnier, Etienne Paubelle, Isabelle Leduc, Nicolas Duployez, Christophe Roumier, Claude Preudhomme, Stéphane Morisset, Jean-Pierre Marolleau, Delphine Lebon

Blood (2022) 140 (Supplement 1): 3225–3226.

https://doi.org/10.1182/blood-2022-164840

Published: 2022

Journal Articles

Single-Unit Transfusion Is Non Inferior to Double Unit Transfusion in Patients with Hematological Disorders Receiving Allogeneic or Autologous Bone Marrow Transplant or Induction Chemotherapy for Acute Leukemia: The 1versus2 Prospective Multicentric Randomized Clinical Trial

Blood (2021) 138 (Supplement 1): 2141.

https://doi.org/10.1182/blood-2021-148270

Published: 2021

Journal Articles

Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program

Blood (2021) 138 (Supplement 1): 262.

https://doi.org/10.1182/blood-2021-147709

Published: 2021

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"

Blood (2021) 138 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2021-146846

Published: 2021

Journal Articles

Impact of Pre-Graft Ruxolitinib on Post-Transplantation Outcome in Myelofibrosis Patients

Sara Villar, Sylvie Chevret, Xavier Poire, Amandine Charbonnier, Patrice Chevallier, Jean-Henri Bourhis, Edouard Forcade, Sylvain Chantepie, David Beauvais, Nicole Raus, Jacques-Olivier Bay, Michael Loschi, Raynier Devillier, Remy Duléry, Patrice Ceballos, Marie Thérèse Rubio, Yves Beguin, Stephanie Nguyen, Marie Robin

Blood (2021) 138 (Supplement 1): 1844.

https://doi.org/10.1182/blood-2021-146380

Published: 2021

Journal Articles

Negative MRD at Day 100 after Allogenic Hematopoietic Stem Cell Transplant (HSCT): The Grail to Reach in Acute Myeloid Leukemia (AML)

Audrey DA Rocha, Alexis Caulier, Magalie Joris, Amandine Charbonnier, Mathieu Sage, Lavinia Merlusca, Lydia Montes, Nicolas Guillaume, Judith Desoutter, Marie-Noëlle Lacassagne, Marine Quint, Thomas Boyer, Véronique Harrivel, Nicolas Duployez, Alice Marceau, Jean-Pierre Marolleau, Delphine Lebon

Blood (2021) 138 (Supplement 1): 2928.

https://doi.org/10.1182/blood-2021-145523

Published: 2021

Journal Articles

Impact of Donor Search Strategy for Allogeneic Hematopoietic Stem Cell Transplantation from Haploidentical or Matched Unrelated Donor for Patients Older Than 55 Years with Hematological Malignancies: Randomized Prospective Phase III Study

Samia Harbi, jean Marie Boher, Edouard Forcade, MD, Patrice Chevallier, MD PhD, Peffault De Latour Régis, Florent Malard, MDPhD, Sylvie Francois, MD, Amandine Charbonnier, MD, Eric Hermet, MD, Claude-Eric Bulabois, MD, Anne Huynh, Ana Berceanu, MD, Thomas Cluzeau, MDPhD, Marie Thérèse Rubio, MD PhD, Sabine Furst, Mohamad Mohty, MD PhD, Raynier Devillier, Didier Blaise, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139440

Published: 2020

Journal Articles

Immunomodulation with Azacytidine and Donor Lymphocyte Infusion Following Sequential Conditioning Allogenic Stem Cell Transplantation Improves Outcome of Unfavorable AML

Magalie Joris, Delphine Lebon, MD, Amandine Charbonnier, MD, Pierre Morel, MD, Berengere Gruson, MD, Alexis Caulier, MD, Caroline Delette, MD, Marie-Noëlle Lacassagne, Nicolas Guillaume, Loïc Garçon, Jean-Pierre Marolleau, MD PhD

Blood (2019) 134 (Supplement_1): 4600.

https://doi.org/10.1182/blood-2019-131314

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myeloid Neoplasm: A Study from the Chronic Malignancies Working Party of the EBMT

Blood (2019) 134 (Supplement_1): 45.

https://doi.org/10.1182/blood-2019-124765

Published: 2019

Journal Articles

Fast CMV and EBV Reactivations after Ruxolitinib for Graft-Versus-Host Disease Treatment

Dujardin Adèle, Pierre Morel, MD, Alexis Caulier, MD, Magalie Joris, MD, Amandine Charbonnier, MD, Berengere Gruson, MD, Marine Quint, Marie-Noëlle Lacassagne, Sandrine Castelain, MD PhD, Jean-Pierre Marolleau, MD PhD, Delphine Lebon, MD

Blood (2019) 134 (Supplement_1): 2007.

https://doi.org/10.1182/blood-2019-123283

Published: 2019

NARROW

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study from the Société Francophone De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC)

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Checkpoint Inhibitors and Allo-SCT in Hodgkin Lymphoma: A Matter of Time - a Study By the SFGM-TC

The Occurrence of Infection and TP53 Mutation Are Risk Factors for Cardiovascular Toxicity of Acute Myeloid Leukemia Induction Therapy

Comparison of Two Reduced Intensity Conditioning Regimens (Baltimore with Clofarabine vs Thiotepa-Busulfan-Fludarabine) in Adults Receiving Peripheral Blood Stem Cell Haploidentical Transplantation for Myeloid Malignancies: A Retrospective Study of the SFGM-TC

Allogeneic Hematopoietic Cell Transplantation in the Elderly Results in Similar Survival with Matched Related or Unrelated and Haploidentical Donors: A Report from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Dose of IV Busulfan in Reduced Toxicity Conditioning Regimen for Older and/or Frail Patients with AML or MDS

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France

Standard Risk-Assessment of AML Doesn't Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy

Single-Unit Transfusion Is Non Inferior to Double Unit Transfusion in Patients with Hematological Disorders Receiving Allogeneic or Autologous Bone Marrow Transplant or Induction Chemotherapy for Acute Leukemia: The 1versus2 Prospective Multicentric Randomized Clinical Trial

Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program

Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"

Impact of Pre-Graft Ruxolitinib on Post-Transplantation Outcome in Myelofibrosis Patients

Negative MRD at Day 100 after Allogenic Hematopoietic Stem Cell Transplant (HSCT): The Grail to Reach in Acute Myeloid Leukemia (AML)

Impact of Donor Search Strategy for Allogeneic Hematopoietic Stem Cell Transplantation from Haploidentical or Matched Unrelated Donor for Patients Older Than 55 Years with Hematological Malignancies: Randomized Prospective Phase III Study

Immunomodulation with Azacytidine and Donor Lymphocyte Infusion Following Sequential Conditioning Allogenic Stem Cell Transplantation Improves Outcome of Unfavorable AML

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myeloid Neoplasm: A Study from the Chronic Malignancies Working Party of the EBMT

Fast CMV and EBV Reactivations after Ruxolitinib for Graft-Versus-Host Disease Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only